Samira Shaikhly Sells 6,250 Shares of Septerna (NASDAQ:SEPN) Stock

Septerna, Inc. (NASDAQ:SEPN) insider Samira Shaikhly sold 6,250 shares of the firm’s stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $35.08, for a total transaction of $219,250.00. Following the transaction, the insider directly owned 793 shares of the company’s stock, valued at $27,818.44. This represents a 88.74% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Samira Shaikhly also recently made the following trade(s):

• On Monday, June 1st, Samira Shaikhly sold 5,935 shares of Septerna stock. The shares were sold at an average price of $28.93, for a total transaction of $171,699.55.
• On Tuesday, May 26th, Samira Shaikhly sold 11,798 shares of Septerna stock. The shares were sold at an average price of $30.06, for a total transaction of $354,647.88.

Septerna Stock Performance

Shares of NASDAQ SEPN opened at $35.80 on Thursday. Septerna, Inc. has a fifty-two week low of $9.85 and a fifty-two week high of $37.01. The company has a 50 day simple moving average of $27.61 and a two-hundred day simple moving average of $26.92. The company has a market capitalization of $1.61 billion, a price-to-earnings ratio of -44.20 and a beta of 2.39.

Septerna (NASDAQ:SEPN) last announced its earnings results on Tuesday, May 12th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.23. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. The business had revenue of $26.52 million during the quarter, compared to the consensus estimate of $16.98 million. On average, analysts forecast that Septerna, Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Septerna

A number of institutional investors have recently made changes to their positions in SEPN. Group One Trading LLC grew its holdings in shares of Septerna by 111.8% during the fourth quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after buying an additional 8,955 shares during the last quarter. Global Retirement Partners LLC purchased a new stake in shares of Septerna during the fourth quarter valued at approximately $35,000. Russell Investments Group Ltd. purchased a new stake in shares of Septerna during the third quarter valued at approximately $36,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Septerna during the fourth quarter valued at approximately $53,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Septerna during the fourth quarter valued at approximately $61,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on SEPN shares. Stifel Nicolaus started coverage on shares of Septerna in a research note on Friday, May 1st. They set a “buy” rating and a $43.00 target price for the company. Zacks Research raised shares of Septerna from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Cantor Fitzgerald reiterated an “overweight” rating and set a $60.00 price target on shares of Septerna in a report on Tuesday, March 10th. JPMorgan Chase & Co. increased their price target on shares of Septerna from $34.00 to $38.00 and gave the company an “overweight” rating in a report on Tuesday, March 24th. Finally, Wells Fargo & Company increased their price target on shares of Septerna from $28.00 to $48.00 and gave the company an “overweight” rating in a report on Tuesday, March 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.78.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.